查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088677

鼻腔給藥與疫苗市場：2026-2032年全球市場預測（按藥物類型、製劑類型、裝置類型、劑量、應用和最終用戶分類）

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鼻內藥物和疫苗市場規模將成長至 796.1 億美元，年複合成長率為 6.14%。

主要市場統計數據
基準年 2025 524.3億美元
預計年份：2026年 554.4億美元
預測年份 2032 796.1億美元
複合年成長率 (%) 6.14%

鼻腔給藥和疫苗接種方式正從一種小眾給藥途徑轉變為急性救命藥物、中樞神經系統療法、呼吸道疫苗以及以患者為中心的慢性病護理的戰略平台。這種給藥途徑已在商業上得到驗證，例如納洛酮鼻噴霧（已於2023年獲得商業性FDA批准作為非處方藥使用）以及咪達唑侖和Diazepam處方箋方藥鼻腔救命療法（適用於無症狀人群）。

對於生物製藥和疫苗研發公司而言，這項機會的基礎在於：藥物可透過血管豐富的鼻黏膜快速全身吸收，避免肝臟首過代謝，實現非侵入性給藥，並有可能誘導上呼吸道局部黏膜免疫。這些優勢支持差異化產品線的開發，例如鼻內疫苗、鼻腦給藥、定量噴霧劑和乾粉鼻製劑，同時也能提高在急診醫學、兒童、老年醫學和分散式醫療機構中的使用便利性。

一項變革性的變化，重新定義了經鼻給藥的前景。

鼻腔給藥和疫苗領域正受到三大變革的重塑：緊急使用授權的實施、聯合製劑技術的進步以及人們對黏膜免疫的重新關注。納洛酮的上市擴大了鼻內給藥在公共衛生領域的應用。同時，FDA核准的鼻內esketamine、咪達唑侖和Diazepam也表明，鼻內給藥平台能夠滿足需要精確給藥、人因檢驗和上市後安全性監測的受監管高價值治療藥物的需求。

人工智慧對鼻腔平台的累積影響

在鼻用藥物和疫苗的研發過程中，人工智慧（AI）正從實驗階段邁向具有累積影響的階段。 AI驅動的製劑篩檢有助於模擬顆粒大小、黏度、輔料相容性、噴霧羽流形狀、液滴分佈、沉積行為和鼻腔停留時間。所有這些因素都會影響鼻腔生物有效性、劑量重複性和患者療效。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美在監管先例和商業化方面處於主導地位，這得益於美國FDA批准上市的鼻噴霧、鼻腔急救藥物以及根據風險評估和緩解策略（REMS）給藥的esketamine。加拿大透過成熟的公共衛生採購體系、疫苗接種基礎設施和患者友善給藥系統，為臨床引入患者友善給藥系統做出了貢獻；而墨西哥則透過擴大藥品分銷範圍和跨境公共衛生的重要性，提高了藥物的可及性。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

歐盟和七國集團在先進的監管科學、疫情防範、臨床證據標準和報銷評估方面展現出最高水準的一致性，並在鼻腔生技藥品、疫苗、急救藥物和中樞神經系統療法領域擁有顯著影響力。北約成員國在醫療措施和緊急應變產品中，優先考慮快速實施、現場準備、儲備和易於培訓的領域，日益提升其在防禦和衛生領域的重要性。

來自主要鼻腔給藥市場關鍵國家的洞察

美國是鼻內給藥的標竿市場，這得益於其FDA已批准納洛酮、esketamine、咪達唑侖和Diazepam的鼻內製劑，以及其在復方製劑、人體因素測試、標籤和上市後監測方面成熟的監管體系。加拿大憑藉其完善的公共衛生體系和疫苗接種基礎設施為鼻內給藥的推廣提供了支持，而墨西哥則透過擴大醫療保險覆蓋範圍、藥品分銷以及對實用、非侵入性療法的需求，增強了北美市場的可及性。

為經鼻給藥領域的領導者提供的實用建議

由於鼻內給藥的效果取決於劑量、噴霧劑型、液滴或顆粒大小、粘度、粘膜纖毛清除率、鼻腔生理以及使用者的技能，因此行業領導者在擴大生產規模之前應優先考慮適應症和器械適用性。對於急救藥物和患者自行接種的疫苗，早期進行人體工學研究至關重要，尤其是對於看護者、壓力較大的患者、兒童或社區用藥的產品。

調查方法

本執行摘要基於多方面、檢驗的二手研究方法，參考了監管資料庫、公共衛生機構、產品標籤、臨床試驗註冊庫、同行評審文獻、疫苗政策參考資料以及公開的衛生監管機構文件。檢驗的批准、指南、已記錄的產品類型和已確立的應用案例優先於未經證實的市場規模估算。

結論

鼻內給藥和疫苗接種正進入一個競爭更加激烈、實證醫學更成熟的階段。在藥物過量解毒、癲癇緊急治療、憂鬱症治療和流感疫苗接種等方面的成熟案例，已證實了此給藥途徑的可靠性。同時，對粘膜疫苗、乾粉製劑、生物製藥以及鼻腦給藥等技術的持續研究，進一步提升了鼻內給藥的策略重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：鼻腔給藥與疫苗市場：依藥物類型分類

  • 止痛藥
    • 非鴉片類藥物
    • 鴉片類藥物
  • 抗組織胺藥
  • 類固醇
  • 疫苗
    • 去活化疫苗
    • 減毒活疫苗
    • 藥效疫苗

第8章：鼻腔給藥與疫苗市場：依劑型類型分類

  • 凝膠配方
  • 液體
  • 粉末製劑

第9章：鼻腔藥物和疫苗傳輸市場：依設備類型分類

  • 霧化器
  • 鼻滴管
  • 鼻噴霧

第10章：鼻腔給藥與疫苗市場：依劑量分類

  • 多次給藥
  • 單一劑量

第11章 鼻腔藥物與疫苗傳遞市場：依應用領域分類

  • 過敏治療
  • 荷爾蒙補充療法
  • 神經系統疾病
  • 疼痛管理
  • 精神疾病
  • 治療性藥物遞送

第12章 鼻腔藥物和疫苗輸送市場：依最終用戶分類

  • 居家照護
  • 醫院和診所
  • 研究和學術機構

第13章：鼻腔藥物和疫苗傳輸市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 鼻腔藥物和疫苗遞送市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 鼻腔藥物和疫苗傳輸市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery LP
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi SA
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market is projected to grow by USD 79.61 billion at a CAGR of 6.14% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 52.43 billion
Estimated Year [2026] USD 55.44 billion
Forecast Year [2032] USD 79.61 billion
CAGR (%) 6.14%

Intranasal drug and vaccine delivery is moving from a niche route of administration to a strategic platform for acute rescue medicines, central nervous system therapies, respiratory immunization, and patient-centric chronic care. The route is commercially validated by products such as naloxone nasal spray, which the U.S. FDA approved for over-the-counter use in 2023, and prescription intranasal rescue therapies including midazolam and diazepam for seizure clusters.

For biopharma and vaccine developers, the opportunity is anchored in rapid systemic absorption through the highly vascular nasal mucosa, avoidance of hepatic first-pass metabolism, noninvasive administration, and the potential induction of local mucosal immunity in the upper respiratory tract. These advantages support differentiated pipelines in nasal vaccines, nose-to-brain delivery, metered-dose sprays, and dry powder nasal formulations, while also improving usability in emergency, pediatric, geriatric, and decentralized-care settings.

Transformative Shifts Reshaping the Intranasal Delivery Landscape

The intranasal drug and vaccine delivery landscape is being reshaped by three verified shifts: emergency-use adoption, combination-product sophistication, and renewed interest in mucosal immunization. Over-the-counter naloxone expanded the public-health role of nasal delivery, while FDA-approved intranasal esketamine, midazolam, and diazepam demonstrated that nasal platforms can support regulated, high-value therapeutics requiring precise dosing, human-factor validation, and post-market safety monitoring.

Vaccine developers are also reassessing nasal delivery after the COVID-19 pandemic exposed limitations in injection-only immunization strategies, particularly for blocking respiratory transmission at mucosal surfaces. FluMist remains an established intranasal influenza vaccine option for eligible people, while countries including India and China advanced mucosal COVID-19 vaccine approaches, reinforcing global interest in respiratory-tract immune protection, needle-free delivery, and scalable immunization formats.

Cumulative Impact of Artificial Intelligence on Intranasal Platforms

Artificial intelligence is becoming cumulative rather than experimental in intranasal drug and vaccine development. AI-enabled formulation screening can help model particle size, viscosity, excipient compatibility, spray plume geometry, droplet distribution, deposition behavior, and nasal residence time, all of which influence intranasal bioavailability, dose reproducibility, and patient outcomes.

For biologics and nasal vaccines, machine learning can support antigen selection, adjuvant optimization, stability prediction, immune-response profiling, and clinical trial enrichment. In commercialization, AI improves pharmacovigilance signal detection, supply planning, patient education, and adherence support for products such as rescue nasal sprays, where real-world usability, rapid onset, and speed of administration are central to clinical value.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America leads in regulatory precedents and commercialization, supported by U.S. FDA approvals for over-the-counter naloxone nasal spray, intranasal seizure rescue medicines, and esketamine administered under a Risk Evaluation and Mitigation Strategy. Canada contributes mature public-health procurement, vaccination infrastructure, and clinical adoption of patient-friendly delivery systems, while Mexico adds access potential through expanding pharmaceutical distribution and cross-border public-health relevance.

Europe benefits from established European Medicines Agency pathways, strong pharmacovigilance systems, sophisticated clinical research networks, and the European Union's focus on preparedness and cross-border health security. The United Kingdom, Germany, France, Italy, and Spain provide important clinical, regulatory, and payer environments for intranasal therapeutics, while broader regional demand is influenced by vaccination policy, respiratory-disease prevention, and acceptance of self-administered medicines.

Asia-Pacific is expanding through China, India, Japan, South Korea, and Australia, where vaccine capacity, respiratory-disease burden, biologics manufacturing, and local innovation policy are accelerating interest in nasal vaccines, nasal sprays, and advanced delivery devices. India and China have already demonstrated national activity in mucosal COVID-19 vaccine development, while Japan, South Korea, and Australia reinforce the region's role through high regulatory standards, device engineering, and advanced healthcare adoption.

Latin America, the Middle East, and Africa are adoption markets with strong public-health relevance, especially for needle-free vaccination, overdose response, pediatric use, and decentralized care. Brazil anchors Latin American demand through public immunization infrastructure, while GCC health systems in the Middle East are investing in emergency readiness, preventive care, and specialty medicine access. Across Africa, intranasal platforms are relevant where simplified administration, cold-chain resilience, and community-based delivery can improve reach.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

The European Union and G7 provide the strongest alignment for advanced regulatory science, pandemic preparedness, clinical evidence standards, and reimbursement evaluation, making them influential for nasal biologics, vaccines, rescue medicines, and central nervous system therapies. NATO countries add defense-health relevance where fast administration, field readiness, stockpiling, and training simplicity are priorities for medical countermeasures and emergency-response products.

BRICS markets offer scale, manufacturing capacity, public-health demand, and rising domestic innovation, particularly across China, India, and Brazil, where vaccine production, respiratory-disease burden, and government-backed health programs support intranasal drug and vaccine delivery. ASEAN countries create growth opportunities through large pediatric populations, expanding immunization programs, urban healthcare modernization, and regional regulatory harmonization efforts. GCC health systems are investing in advanced hospitals, preventive care, emergency-response readiness, and specialty access, supporting premium adoption of innovative intranasal products where clinical differentiation and convenience are well demonstrated.

Key Country Insights Across Major Intranasal Delivery Markets

The United States is the benchmark market for intranasal drug delivery because of FDA precedents in naloxone, esketamine, midazolam, and diazepam nasal products, as well as mature frameworks for combination products, human-factor testing, labeling, and post-market surveillance. Canada supports adoption through established public-health systems and vaccination infrastructure, while Mexico adds North American access potential through expanding healthcare coverage, pharmaceutical distribution, and demand for practical, noninvasive therapies.

Brazil anchors Latin American relevance through public immunization infrastructure, respiratory-health priorities, and growing pharmaceutical capabilities. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong clinical trial networks, advanced specialist care, and established reimbursement review processes, although payer scrutiny requires clear evidence for onset of action, adherence, safety, and therapeutic differentiation. Russia remains relevant through domestic vaccine capacity and public-sector interest in locally produced immunization technologies.

China and India are strategic for intranasal vaccine development, manufacturing scale, respiratory-disease prevention, and cost-efficient delivery formats, with both countries having advanced mucosal COVID-19 vaccine approaches during the pandemic era. Japan, Australia, and South Korea contribute high regulatory standards, sophisticated device adoption, strong clinical capabilities, and demand for patient-friendly therapies, making them important markets for validated nasal sprays, dry powder systems, and next-generation intranasal biologics.

Actionable Recommendations for Intranasal Delivery Leaders

Industry leaders should prioritize indication-device fit before scale-up, because nasal delivery performance depends on dose volume, plume geometry, droplet or particle size, viscosity, mucociliary clearance, nasal physiology, and user technique. Early human-factor studies are essential for rescue medicines and self-administered vaccines, particularly when products are intended for caregivers, patients under stress, pediatric populations, or community-based administration.

Biopharma teams should build evidence packages around bioavailability, onset of action, mucosal immune markers where relevant, immunogenicity, stability, dose reproducibility, device reliability, and real-world adherence. Partnerships with device engineers, contract development and manufacturing organizations, AI formulation platforms, clinical networks, and public-health agencies can shorten development timelines while improving regulatory confidence, product usability, and market access readiness.

Research Methodology

This executive summary is based on triangulated secondary research from regulatory databases, public-health agencies, product labels, clinical-trial registries, peer-reviewed literature, vaccine policy references, and publicly available health authority documentation. Priority was given to verified approvals, guidance, documented product categories, and established clinical use cases rather than unsupported market-size estimates.

The methodology evaluates intranasal drug delivery and nasal vaccine delivery by therapeutic area, dosage form, device type, regulatory pathway, regional adoption, public-health relevance, and commercial readiness. Findings were validated through cross-comparison of FDA, EMA, CDC, WHO, and national health authority references where applicable, with emphasis on traceable evidence related to safety, efficacy, usability, mucosal immunology, and combination-product performance.

Conclusion

Intranasal drug and vaccine delivery is entering a more competitive and evidence-driven phase. Proven use cases in overdose reversal, seizure rescue, depression treatment, and influenza vaccination have established the route's credibility, while ongoing work in mucosal vaccines, dry powder delivery, biologics, and nose-to-brain delivery expands its strategic importance.

The strongest opportunities will favor developers that combine rigorous formulation science, validated delivery devices, AI-enabled optimization, human-factor evidence, and clear regulatory documentation. As health systems demand faster, needle-free, scalable, and patient-friendly interventions, intranasal platforms are positioned for sustained relevance across emergency care, immunization, neurology, psychiatry, and respiratory health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Intranasal Drug & Vaccine Delivery Market, by Drug Type

  • 7.1. Analgesics
    • 7.1.1. Non-opioids
    • 7.1.2. Opioids
  • 7.2. Antihistamines
  • 7.3. Steroids
  • 7.4. Vaccines
    • 7.4.1. Inactivated Vaccines
    • 7.4.2. Live Attenuated Vaccines
    • 7.4.3. mRNA-based Vaccine

8. Intranasal Drug & Vaccine Delivery Market, by Formulation Type

  • 8.1. Gel Formulations
  • 8.2. Liquid Formulations
  • 8.3. Powder Formulations

9. Intranasal Drug & Vaccine Delivery Market, by Device Type

  • 9.1. Atomizer
  • 9.2. Nasal Dropper
  • 9.3. Nasal Spray

10. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 10.1. Multi-dose
  • 10.2. Unit-dose

11. Intranasal Drug & Vaccine Delivery Market, by Application

  • 11.1. Allergy Treatment
  • 11.2. Hormone Replacement
  • 11.3. Neurological Conditions
  • 11.4. Pain Management
  • 11.5. Psychiatric Disorders
  • 11.6. Therapeutic Drug Delivery

12. Intranasal Drug & Vaccine Delivery Market, by End-User

  • 12.1. Homecare
  • 12.2. Hospitals & Clinics
  • 12.3. Research & Academic Institution

13. Intranasal Drug & Vaccine Delivery Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Intranasal Drug & Vaccine Delivery Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intranasal Drug & Vaccine Delivery Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Altimmune, Inc.
  • 17.2. AptarGroup, Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Bausch Health Companies Inc.
  • 17.5. Bayer AG
  • 17.6. Becton, Dickinson, and Company
  • 17.7. Bharat Biotech Ltd.
  • 17.8. Boehringer Ingelheim International GmbH.
  • 17.9. Catalent, Inc
  • 17.10. DCA Design International Limited
  • 17.11. Emergent BioSolutions Inc.
  • 17.12. GlaxoSmithKline PLC
  • 17.13. Hovione Limited
  • 17.14. Impel Pharmaceuticals LLC.
  • 17.15. Indivior PLC
  • 17.16. Intersect ENT by Medtronic plc
  • 17.17. Intertek Group PLC
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Kindeva Drug Delivery L.P.
  • 17.20. Merck & Co., Inc.
  • 17.21. Neurelis, Inc.
  • 17.22. Novartis AG
  • 17.23. OptiNose, Inc.
  • 17.24. Pfizer Inc.
  • 17.25. Recipharm AB.
  • 17.26. Sanofi S.A.
  • 17.27. Teleflex Incorporated
  • 17.28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GEL FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GEL FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GEL FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATOMIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ATOMIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATOMIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NASAL DROPPER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NASAL DROPPER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NASAL DROPPER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NASAL SPRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NASAL SPRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NASAL SPRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTI-DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTI-DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTI-DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UNIT-DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UNIT-DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UNIT-DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE,